The newer diabetes drug classes have also benefited from large recent clinical trials showing that SGLT‐2 inhibitors and GLP‐1 receptor agonists prevent major adverse cardiovascular events and progression of kidney disease.1, 2. Here, GLP1R is linked to diabetes mellitus.